Diaxonhit Share Price Euronext Paris
Equities
FR0004054427
Biotechnology & Medical Research
Sales 2024 * | 138M 150M 11.77B | Sales 2025 * | 148M 161M 12.63B | Capitalization | 146M 158M 12.42B |
---|---|---|---|---|---|
Net income 2024 * | 9M 9.77M 768M | Net income 2025 * | 11M 11.94M 938M | EV / Sales 2024 * | 0.98 x |
Net cash position 2024 * | 9.9M 10.74M 845M | Net cash position 2025 * | 32.8M 35.59M 2.8B | EV / Sales 2025 * | 0.76 x |
P/E ratio 2024 * |
15.3
x | P/E ratio 2025 * |
12
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61.33% |
Managers | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 18/06/17 |
Director of Finance/CFO | 43 | 30/09/22 | |
Cathie Marsais
COO | Chief Operating Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 18/06/17 |
Director/Board Member | 68 | 03/11/09 | |
Director/Board Member | 67 | 14/06/17 |
1st Jan change | Capi. | |
---|---|---|
+52.36% | 58.06B | |
-3.86% | 40.53B | |
+36.78% | 38.99B | |
-12.01% | 26.56B | |
+14.13% | 26.7B | |
-21.62% | 18.98B | |
+0.21% | 12.17B | |
+25.96% | 11.92B | |
+23.02% | 12B |